Close
Close

Biomarker for Sanfilippo Disease

Access Programs

Disease Information

Descriptive Information
Brief Title † Biomarker for Sanfilippo Disease
Official Title † Biomarker for Sanfilippo Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL
Brief Summary Development of a new MS-based biomarker for the early and sensitive diagnosis of Sanfilippo Type A-B-C-D disease from plasma and saliva. Testing for clinical robustness, specificity and long-term stability of the biomarker.
Detailed Description The Mucopolysaccharidoses (MPS Disorders) are a group of rare genetic disorders caused by the deficiency of one of the lysosomal enzymes, resulting in an inability to metabolize complex carbohydrates (mucopolysaccharides) into simpler molecules. High concentrations of mucopolysaccharides in the cells of the central nervous system, including the brain, cause the neurological and developmental deficits that accompany these disorders. Lysosomal enzymes are found in the lysosome, a very small membrane-contained body (or-ganelle) found in the cytoplasm of most cells. The lysosome is often called the "waste dis-posal plant" of the cell. The accumulation of these large, undegraded mucopolysaccharides in the cells of the body is the cause of a number of physical symptoms and abnormalities. MPS-III (Sanfilippo Syndrome) is one of seven MPS Disorders. It is an inborn error of metab-olism that is transmitted as an autosomal recessive genetic disorder. MPS-lll has been cate-gorized into four subtypes: MPS-III Type A, MPS-III Type B, MPS-III Type C, and MPS-III Type D depending on the gene defect (MPS3A - SGSH gene, MPS3B - NAGLU gene, MPS3C - HGSNAT, MPS3D - GNS gene). All types are associated with some degree of mental deterioration, but the severity depends on the particular type of MPS-lll. Several phys-ical defects may be present, and the severity of these defects varies with the type of MPS-III. In the case of each type of MPS-III, abnormal amounts of a specific, chemically complex molecule is excreted in the urine. The excreted chemical is the same for each of the four types of MPS-III, since the defective gene involves a different step, and thus a different en-zyme, in the deconstruction of the same mucopolysaccharide. By testing for one or another of these enzymes, the variant type may be readily identified. Symptoms Patients with Sanfilippo Syndrome (MPS Type III) usually appear normal at birth, but mental retardation and developmental delay is usually evident by age 3-5 years. Mental and motor development reaches a peak by 3-6 years of age after which behavioral disturbances and intellectual decline usually occur. However, hyperactivity and irritability may become obvious earlier. The following symptoms are usually apparent by approximately age 10: neurological deficits and signs, wobbly and erratic gait and difficulty walking (ataxia), hyperactivity (hyperkinetic syndrome), mental retardation, stiff joints, hernias, enlarged liver and/or spleen (hepatosple-nomegaly).Growth is usually minimally affected; the head may be enlarged, and abnormal hairiness (hirsutism) may occur. Mild coarsening of facial features also characterizes this disorder. In some cases deafness may also occur. All four varieties of MPS-III are autosomal recessive genetic disorders. The gene abnormalities associated with MSS-IIIA, MPS-IIIB, MPS-IIIC and MPS-IIID have been identified. Genetic diseases are determined by the combination of genes for a particular trait that are on the chromosomes received from the father and the mother. Recessive genetic disorders occur when an individual inherits the same abnormal gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and, therefore, have an af-fected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%. The risk is the same for males and females. All individuals carry 4-5 abnormal genes. Parents who are close relatives (consanguineous) have a higher chance than unrelated parents to both carry the same abnormal gene, which increases the risk to have children with a recessive genetic disorder.
Study Phase N/A
Study Type † Observational
Study Design † Observational Model: Cohort, Time Perspective: Prospective
Primary Outcome Measure † Development of a new MS-based biomarker for the early and sensitive diagnosis of Sanfilippo Type A-B-C-D disease from plasma and saliva
Secondary Outcome Measure † Testing for clinical robustness, specificity and long-term stability of the biomarker
Condition † Mucopolysaccharidosis Type 3 A Mucopolysaccharidosis Type 3 B Mucopolysaccharidosis Type 3 C Mucopolysaccharidosis Type 3 D Heparan Sulfate Sulfatase Deficiency
Intervention †
Study Arms / Comparison Groups Observation Patients with Sanfilippo Type A-B-C-D disease or patients with high-grade suspicion for Sanfilippo Type A-B-C-D disease submitted to the participating centers should be included into the study.
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status †
Estimated Enrollment † 50
Start Date † November 2014
Completion Date December 2017
Primary Completion Date November 2017
Eligibility Criteria † Inclusion Criteria: - Informed consent will be obtained from the patient or the parents before any study related procedures. - Patients of both gender older than 2 month - The patient has a diagnosis of Sanfilippo Type A-B-C-D disease or high-grade suspicion for Sanfilippo Type A-B-C-D disease High-grade suspicion present, if one or more criteria are valid: - Positive family anamnesis for Sanfilippo Type A-B-C-D disease - Dysostosis multiplex without identifiable cause - Splenomegaly without identifiable cause - Hepatomegaly without identifiable cause - Heparan sulfate excretion in urine - CNS involvement without identifiable cause Exclusion Criteria: - No Informed consent from the patient or the parents before any study related pro-cedures - Patient of both gender younger than 2 month - No diagnosis of Sanfilippo Type A-B-C-D disease or no valid criteria for high-grade suspicion of Sanfilippo Type A-B-C-D disease
Gender Both
Ages 2 Months - N/A
Accepts Healthy Volunteers No
Contacts †† Arndt Rolfs, Prof., +49 381 494, arndt.rolfs@med.uni-rostock.de
Location Countries † Germany
Administrative Information
NCT ID † NCT02298686
Organization ID BSF01-2014
Secondary IDs ††
Responsible Party Principal Investigator
Study Sponsor † University of Rostock
Collaborators †† Centogene AG Rostock
Investigators † Principal Investigator: Arndt Rolfs, Prof., University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration
Information Provided By
Verification Date April 2016
First Received Date † October 23, 2014
Last Updated Date April 12, 2016
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Related Videos
by Harish Ravi
3,127 views
by Abidemi Uruejoma
10,391 views
Free Newsletter